Johnson & Johnson (JNJ) to Release Quarterly Earnings on Wednesday

Johnson & Johnson (NYSE:JNJ - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Wednesday, July 16th. Analysts expect Johnson & Johnson to post earnings of $2.65 per share and revenue of $22.85 billion for the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.500-10.700 EPS.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded up $0.28 during mid-day trading on Wednesday, hitting $156.07. The company's stock had a trading volume of 6,139,971 shares, compared to its average volume of 8,049,676. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $375.52 billion, a P/E ratio of 17.36, a P/E/G ratio of 2.35 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock's fifty day moving average price is $153.67 and its two-hundred day moving average price is $154.25.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were given a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.33%. Johnson & Johnson's payout ratio is 57.84%.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Barclays lowered their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Bank of America lowered their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Institutional Investors Weigh In On Johnson & Johnson

A hedge fund recently raised its stake in Johnson & Johnson stock. Brighton Jones LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,876 shares of the company's stock after acquiring an additional 6,332 shares during the period. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 at the end of the most recent quarter. Institutional investors own 69.55% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.